Preclinical validation of PKC412 as a therapy candidate for epidermolysis bullosa simplex across multiple keratin pathogenic variants
PKC412 markedly enhanced intercellular cohesion and stress resilience in patient-derived EBS keratinocytes, both in monolayer and three-dimensional culture systems. These findings highlight PKC412 as a promising therapeutic candidate for the treatment of EBS.
Authors
- M. Bishr Omary (ORCID: https://orcid.org/0000-0002-8624-2347)
- Bernd Hoffmann (ORCID: https://orcid.org/0000-0002-3803-8835)
- Thomas M. Magin (ORCID: https://orcid.org/0000-0001-7016-2409)
- Rudolf Merkel (ORCID: https://orcid.org/0000-0003-3178-3282)
- Katrin Rietscher (ORCID: https://orcid.org/0000-0002-9304-7603)
- Cristina Has (ORCID: https://orcid.org/0000-0001-6066-507X)
- A Kraft
- Henriette Jopp
Institutions
- Rutgers, The State University of New Jersey (US)
- University of Freiburg (DE)
- Forschungszentrum Jülich (DE)
- University Medical Center Freiburg (DE)
- Johnson University (US)
- University Hospital Leipzig (DE)
- Klinik und Poliklinik für Neurologie (DE)
- RWTH Aachen University (DE)
- Leipzig University (DE)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1093/bjd/ljaf195
- Citations
- 2
- Primary Topic
- Skin and Cellular Biology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.30
Funders
- Universität Leipzig
- DEBRA Austria